$REGN News

Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $854

Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $730

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $696

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $769

Benchmark Upgrades Regeneron Pharmaceuticals to Buy, Announces $185 Price Target

HSBC Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $880

Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $750

Regeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiran

Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain

Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?

Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative?

Regeneron's Applications for gMG Drug Accepted by FDA and EMA

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Regeneron Pharmaceuticals Announces That Both The FDA And EMA Have Accepted Regulatory Applications For Cemdisiran To Treat Adult Patients With Generalized Myasthenia Gravis Who Are Anti-Acetylcholine Receptor Antibody-Positive

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years